Resource Logo
NLM AIDSLINE

[Primary prevention of cerebral toxoplasmosis in patients with HIV infection: results of a double-blind randomized trial, pyrimethamine versus placebo]




 

Rev Med Interne. 1993;14(10):1002. Unique Identifier : AIDSLINE

To assess the efficacy of pyrimethamine (Pyr) for primary prophylaxis of cerebral toxoplasmosis (CT) in HIV patients (pts), 554 pts were randomized in a double-blind, placebo-controlled trial (mean follow-up: 14 months). The intent-to-treat analysis found no significant difference in the incidence of ct at 1 year: 12% (Pyr) versus 13% (Pcb) nor in survival. Side-effects leading to stop the study drug were more frequent in Pyr group, especially cutaneous rashes: 8% (Pyr) versus 2% (Pcb).

Double-Blind Method English Abstract Human HIV Infections/*COMPLICATIONS *HIV-1 Placebos Pyrimethamine/*THERAPEUTIC USE Toxoplasmosis, Cerebral/ETIOLOGY/*PREVENTION & CONTROL CLINICAL TRIAL JOURNAL ARTICLE RANDOMIZED CONTROLLED TRIAL



 




Information in this article was accurate in September 30, 1994. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.